- Home
- LNZA vs BMEA Comparison
LNZA vs BMEA Comparison
Compare LNZA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNZA
- BMEA
- Stock Information
- Founded
- LNZA 2005
- BMEA 2017
- Country
- LNZA United States
- BMEA United States
- Employees
- LNZA N/A
- BMEA N/A
- Industry
- LNZA Major Chemicals
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- LNZA Industrials
- BMEA Health Care
- Exchange
- LNZA Nasdaq
- BMEA Nasdaq
- Market Cap
- LNZA 65.7M
- BMEA 65.8M
- IPO Year
- LNZA N/A
- BMEA 2021
- Fundamental
- Price
- LNZA $0.29
- BMEA $1.86
- Analyst Decision
- LNZA Hold
- BMEA Strong Buy
- Analyst Count
- LNZA 2
- BMEA 10
- Target Price
- LNZA $2.00
- BMEA $21.00
- AVG Volume (30 Days)
- LNZA 1.8M
- BMEA 1.5M
- Earning Date
- LNZA 08-07-2025
- BMEA 07-30-2025
- Dividend Yield
- LNZA N/A
- BMEA N/A
- EPS Growth
- LNZA N/A
- BMEA N/A
- EPS
- LNZA N/A
- BMEA N/A
- Revenue
- LNZA $48,831,000.00
- BMEA N/A
- Revenue This Year
- LNZA $58.17
- BMEA N/A
- Revenue Next Year
- LNZA $10.92
- BMEA N/A
- P/E Ratio
- LNZA N/A
- BMEA N/A
- Revenue Growth
- LNZA N/A
- BMEA N/A
- 52 Week Low
- LNZA $0.14
- BMEA $1.29
- 52 Week High
- LNZA $2.74
- BMEA $13.07
- Technical
- Relative Strength Index (RSI)
- LNZA 52.65
- BMEA 48.52
- Support Level
- LNZA $0.27
- BMEA $1.77
- Resistance Level
- LNZA $0.31
- BMEA $1.97
- Average True Range (ATR)
- LNZA 0.03
- BMEA 0.13
- MACD
- LNZA -0.00
- BMEA 0.01
- Stochastic Oscillator
- LNZA 69.74
- BMEA 66.67
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a carbon management company transforming waste carbon into sustainable fuels, fabrics, packaging, and nutrition. Its goal is to advance a circular economy where carbon is reused rather than wasted, reducing reliance on virgin fossil resources and supporting supply chain resilience. The company operates in North America, Europe, Middle East, Africa (EMEA), Asia, and Australia.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small-molecule drugs to treat patients with metabolic diseases. The company uses its proprietary FUSION System discovery platform to develop a pipeline of novel small-molecule product candidates. Its principal clinical program's drug candidate, icovamenib, is being developed as an orally bioavailable, selective covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity. The company is also developing BMF-650, an investigational, oral small-molecule GLP-1 RA, which has the potential to be a therapeutic option for diabetes and obesity.